These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27436386)

  • 41. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Zavascki AP; Bulitta JB; Landersdorfer CB
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1333-53. PubMed ID: 24191943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa.
    Berditsch M; Jäger T; Strempel N; Schwartz T; Overhage J; Ulrich AS
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5288-96. PubMed ID: 26077259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colistin and tobramycin resistance during long- term use of selective decontamination strategies in the intensive care unit: a post hoc analysis.
    Wittekamp BH; Oostdijk EA; de Smet AM; Bonten MJ
    Crit Care; 2015 Mar; 19(1):113. PubMed ID: 25880968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
    Vaara M; Sader HS; Rhomberg PR; Jones RN; Vaara T
    J Antimicrob Chemother; 2013 Mar; 68(3):636-9. PubMed ID: 23134658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic combinations of polymyxins.
    Lenhard JR; Nation RL; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa.
    Mitsugui CS; Tognim MC; Cardoso CL; Carrara-Marroni FE; Botelho Garcia L
    Int J Antimicrob Agents; 2011 Nov; 38(5):447-50. PubMed ID: 21872449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.
    Draper LA; Cotter PD; Hill C; Ross RP
    BMC Microbiol; 2013 Sep; 13():212. PubMed ID: 24069959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial.
    de Jonge E; Schultz MJ; Spanjaard L; Bossuyt PM; Vroom MB; Dankert J; Kesecioglu J
    Lancet; 2003 Sep; 362(9389):1011-6. PubMed ID: 14522530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro synergistic activity of some chinolinic compounds combined with beta-lactam antibiotics against gram-positive and gram-negative clinical isolates.
    Ravagnan G; Piccolomini R; Speciale AM; Russo G; Renzini G
    Chemotherapy; 1985; 31(3):191-9. PubMed ID: 3996087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
    Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
    Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.
    Galani I; Orlandou K; Moraitou H; Petrikkos G; Souli M
    Int J Antimicrob Agents; 2014 Apr; 43(4):370-4. PubMed ID: 24560919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants during hospitalization in neonatal intensive care unit (NICU).
    Yap PS; Ahmad Kamar A; Chong CW; Yap IK; Thong KL; Choo YM; Md Yusof MY; Teh CS
    Pathog Glob Health; 2016 Sep; 110(6):238-246. PubMed ID: 27650884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogens causing blood stream infections and their drug susceptibility profile in immunocompromised patients.
    Fayyaz M; Mirza IA; Ikram A; Hussain A; Ghafoor T; Shujat U
    J Coll Physicians Surg Pak; 2013 Dec; 23(12):848-51. PubMed ID: 24304986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Gram-negative bacterial infections by potentiation of antibiotics.
    Zabawa TP; Pucci MJ; Parr TR; Lister T
    Curr Opin Microbiol; 2016 Oct; 33():7-12. PubMed ID: 27232956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.